NYMC Faculty Publications
Novel Antidotes for Target Specific Oral Anticoagulants
Author Type(s)
Faculty
DOI
10.1186/s40164-015-0020-3
Journal Title
Experimental Hematology & Oncology
First Page
25
Last Page
25
Document Type
Article
Publication Date
1-1-2015
Department
Medicine
Disciplines
Medicine and Health Sciences
Abstract
Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977.
Recommended Citation
Das, A., & Liu, D. (2015). Novel Antidotes for Target Specific Oral Anticoagulants. Experimental Hematology & Oncology, 4, 25-25. https://doi.org/10.1186/s40164-015-0020-3
COinS
